Optimizing the management of her2-positive early breast cancer: the clinical reality

Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with her2-pos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Verma, Su., Lavasani, S., Mackey, J., Pritchard, K., Clemons, M., Dent, S., Latreille, J., Lemieux, J., Provencher, L., Verma, Sh., Chia, S., Wang, B., Rayson, D.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2010
Matèries:
Medical Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913825/
https://ncbi.nlm.nih.gov/pubmed/20697511
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars